Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

Technology appraisal guidance
Reference number: TA258
Published: 27 June 2012

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): AstraZeneca UK

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): AstraZeneca UK

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): AstraZeneca UK
10 May 2012
(169.75 Kb 49 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 08 May 2012